RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of MNPR
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Monopar Therapeutics Inc.
(Updated on Jul 03, 2024)

Sell candidate since Jul 02, 2024 Loss -2.31% PDF

The Monopar Therapeutics Inc. stock price fell by -2.31% on the last day (Wednesday, 3rd Jul 2024) from $0.720 to $0.703. During the last trading day the stock fluctuated 2.04% from a day low at $0.700 to a day high of $0.714. The price has fallen in 6 of the last 10 days and is down by -14.95% for this period. Volume has increased on the last day by 9 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 54 thousand shares were bought and sold for approximately $37.98 thousand.

The stock lies in the lower part of a very wide and strong rising trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $0.662 is broken, it will firstly indicate a slower rate of rising, but may also be an early warning for a trend shift. Given the current short-term trend, the stock is expected to rise 17.56% during the next 3 months and, with a 90% probability hold a price between $0.779 and $1.14 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

MNPR Signals & Forecast

There are few to no technical positive signals at the moment. The Monopar Therapeutics Inc. stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. On corrections up, there will be some resistance from the lines at $0.743 and $0.729. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, June 14, 2024, and so far it has fallen -25.17%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Monopar Therapeutics Inc. gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs". The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Monopar Therapeutics Inc. stock

Monopar Therapeutics Inc. finds support from accumulated volume at $0.673 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0143 between high and low, or 2.04%. For the last week, the stock has had daily average volatility of 4.38%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (MNPR) For The Upcoming Trading Day Of Friday 5th

For the upcoming trading day on Friday, 5th we expect Monopar Therapeutics Inc. to open at $0.706, and during the day (based on 14 day Average True Range), to move between $0.626 and $0.781, which gives a possible trading interval of +/-$0.0777 (+/-11.05%) up or down from last closing price. If Monopar Therapeutics Inc. takes out the full calculated possible swing range there will be an estimated 22.11% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.673 (4.32%) than the resistance at $0.770 (9.45%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Monopar Therapeutics Inc. stock A Buy?

The Monopar Therapeutics Inc. stock holds several negative signals and despite the positive trend, we believe Monopar Therapeutics Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.709 Sell Candidate Unchanged

Predicted Opening Price for Monopar Therapeutics Inc. of Friday, July 5, 2024

Fair opening price July 5, 2024 Current price
$0.706 ( 0.355%) $0.703

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for MNPR

Fibonacci Support & Resistance Levels

Level Price
R3 0.720 2.39%
R2 0.715 1.61%
R1 0.711 1.13%
Price 0.703
S1 0.700 -0.421%
S2 0.697 -0.90%
S3 0.692 -1.68%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0.81 14.44%
R2 0.770 9.47%
R1 0.770 9.45%
Price 0.703
S1 0.673 -4.32%
S2 0.640 -9.01%
S3 0.601 -14.56%

FAQ

What is the symbol for Monopar Therapeutics Inc. Stock and on which exchange is it traded?
The symbol for Monopar Therapeutics Inc. is MNPR and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Monopar Therapeutics Inc. Stock?
The Monopar Therapeutics Inc. stock holds several negative signals and despite the positive trend, we believe Monopar Therapeutics Inc. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Monopar Therapeutics Inc. Stock?
Monopar Therapeutics Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Monopar Therapeutics Inc. Stock.

What's the current price of Monopar Therapeutics Inc. Stock?
As of the end of day on the Jul 03, 2024, the price of an Monopar Therapeutics Inc. (MNPR) share was $0.703.

What is the 52-week high and low for Monopar Therapeutics Inc. Stock?
The 52-week high for Monopar Therapeutics Inc. Stock is $1.73 and the 52-week low is $0.274.

What is the market capitalization of Monopar Therapeutics Inc. Stock?
As of the Jul 03, 2024, the market capitalization of Monopar Therapeutics Inc. is 12.298M.

When is the next earnings date for Monopar Therapeutics Inc.?
The upcoming earnings date for Monopar Therapeutics Inc. is Aug 08, 2024.
Click to get the best stock tips daily for free!

About Monopar Therapeutics Inc.

Monopar Therapeutics. Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubic... MNPR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT